GlobeImmune (GlobeImmune) EBIT per Share : $-0.39 (TTM As of Mar. 2016)

View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune EBIT per Share?

GlobeImmune's EBIT per Share for the three months ended in Mar. 2016 was $-0.15. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.39.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for GlobeImmune's EBIT per Share or its related term are showing as below:

GBIM's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

GlobeImmune's EBIT for the three months ended in Mar. 2016 was $-0.86 Mil.

GlobeImmune EBIT per Share Historical Data

The historical data trend for GlobeImmune's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeImmune EBIT per Share Chart

GlobeImmune Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

EBIT per Share

Get a 7-Day Free Trial

-142.97

-20.99

80.08

-4.24

-0.48

GlobeImmune Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Mar12	Jun12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
EBIT per Share	Get a 7-Day Free Trial															-0.27	-0.23	0.13	-0.14	-0.15

GlobeImmune EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

GlobeImmune's EBIT per Share for the fiscal year that ended in Dec. 2015 is calculated as

	EBIT per Share		(A: Dec. 2015 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.767	/	5.752
=	-0.48

GlobeImmune's EBIT per Share for the quarter that ended in Mar. 2016 is calculated as

	EBIT per Share		(Q: Mar. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.862	/	5.752
=	-0.15

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.39

GlobeImmune (OTCPK:GBIM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

GlobeImmune EBIT per Share Related Terms

Thank you for viewing the detailed overview of GlobeImmune's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeImmune (GlobeImmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 Infinite Drive, Louisville, CO, USA, 80027

Website

http://www.globeimmune.com

GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.

Executives

Augustine Lawlor	director	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell	director
S. Edward Torres	director	C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh	other: Former 10% Owner	265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner	other: Former 10% Owner	C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p.	other: Former 10% Owner	44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag	director
Rodell Timothy C Jr	director, officer: CEO & Pres	201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp	10 percent owner	50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines